Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) were up 7.1% during mid-day trading on Tuesday . The stock traded as high as $21.67 and last traded at $21.56, approximately 1,016,623 shares were traded during trading. An increase of 77% from the average daily volume of 572,945 shares. The stock had previously closed at $20.13.

Several equities analysts have recently issued reports on AIMT shares. Cantor Fitzgerald reiterated a “buy” rating and set a $45.00 target price on shares of Aimmune Therapeutics in a report on Thursday, May 9th. Royal Bank of Canada decreased their price objective on shares of Aimmune Therapeutics to $50.00 and set an “outperform” rating for the company in a report on Friday. Credit Suisse Group assumed coverage on shares of Aimmune Therapeutics in a report on Tuesday, May 21st. They issued an “outperform” rating and a $30.00 price objective for the company. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 30th. Finally, Wedbush set a $79.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a report on Thursday, July 11th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $42.50.

The stock has a market cap of $1.26 billion, a P/E ratio of -5.87 and a beta of -0.07. The business has a fifty day moving average of $19.51. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.65 and a quick ratio of 7.65.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.08). During the same period in the prior year, the firm posted ($0.91) EPS. As a group, equities research analysts predict that Aimmune Therapeutics Inc will post -3.82 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc grew its position in Aimmune Therapeutics by 29.1% in the 4th quarter. Legal & General Group Plc now owns 18,273 shares of the biotechnology company’s stock worth $437,000 after purchasing an additional 4,123 shares during the period. Botty Investors LLC bought a new stake in Aimmune Therapeutics in the 1st quarter worth approximately $2,505,000. Norges Bank bought a new stake in Aimmune Therapeutics in the 4th quarter worth approximately $6,035,000. DekaBank Deutsche Girozentrale grew its position in Aimmune Therapeutics by 21.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 15,100 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 2,700 shares during the period. Finally, Pearl River Capital LLC bought a new stake in Aimmune Therapeutics in the 1st quarter worth approximately $28,000. Institutional investors own 75.85% of the company’s stock.

Aimmune Therapeutics Company Profile (NASDAQ:AIMT)

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

See Also: Cost of Goods Sold (COGS)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.